Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors
We have initially shown that DC/ApoNec vaccine can induce protection against the poorly immunogenic B16F1 melanoma in mice. The population of DC obtained for vaccination after 7. days culture with murine GM-CSF is heterogeneous and presents about 60% of CD11c+ DC. Therefore, our purpose was to ident...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_0264410X_v31_n2_p354_Campisano |
| Aporte de: |
| id |
todo:paper_0264410X_v31_n2_p354_Campisano |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_0264410X_v31_n2_p354_Campisano2023-10-03T15:12:50Z Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors Campisano, S. Mac Keon, S. Gazzaniga, S. Ruiz, M.S. Traian, M.D. Mordoh, J. Wainstok, R. Bone marrow Dendritic cell Melanoma Vaccine apoptotic and necrotic cell vaccine B7 antigen CD11b antigen CD83 antigen CD86 antigen dendritic cell vaccine glycoprotein p 15095 granulocyte macrophage colony stimulating factor interleukin 12 major histocompatibility antigen class 2 unclassified drug vaccine animal cell animal experiment animal model article bone marrow cell differentiation cell fractionation cell population cell type coculture controlled study dendritic cell immunogenicity macrophage male mouse neutrophil nonhuman phagocyte phenotype precursor priority journal tumor cell Animals Antigen Presentation Antigens, CD11c Antigens, Surface Bone Marrow Cells Cancer Vaccines Cell Differentiation Cell Line, Tumor Coculture Techniques Dendritic Cells Granulocyte-Macrophage Colony-Stimulating Factor Interleukin-12 Lymphocyte Activation Male Melanoma, Experimental Mice Mice, Inbred BALB C Mice, Inbred C57BL Neutrophils We have initially shown that DC/ApoNec vaccine can induce protection against the poorly immunogenic B16F1 melanoma in mice. The population of DC obtained for vaccination after 7. days culture with murine GM-CSF is heterogeneous and presents about 60% of CD11c+ DC. Therefore, our purpose was to identify the phenotype of the cells obtained after differentiation and its immunogenicity once injected. DC were separated with anti-CD11c microbeads and the two populations identified in terms of CD11c positivity (DC+ and DC-) were also studied. Approximately 26.6% of the cells in DC+ fraction co-expressed CD11c+ and F4/80 markers and 75.4% were double positive for CD11c and CD11b markers. DC+ fraction also expressed Ly6G. DC- fraction was richer in CD11c-/F4/80+ macrophages (44.7%), some of which co-expressed Ly6G (41.8%), and F4/80-/Ly6-G+ neutrophils (34.6%). Both DC+ and DC- fractions displayed similar capacity to phagocyte and endocyte antigens and even expressed levels of MHC Class II and CD80, CD83 and CD86 costimulatory molecules similar to those in the DC fraction. However, only DC/ApoNec vaccine was capable to induce protection in mice (p<. 0.01). After 24. h co-culture, no detectable level of IL-12 was recorded in DC/ApoNec vaccine, either in supernatant or intracellularly. Therefore, the protection obtained with DC/ApoNec vaccine seemed to be independent of the vaccine's ability to secrete this inflammatory cytokine at the time of injection. In conclusion, we demonstrated that all cell types derived from the culture of mouse bone marrow with GM-CSF are necessary to induce antitumor protection in vivo. © 2012 Elsevier Ltd. Fil:Gazzaniga, S. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_0264410X_v31_n2_p354_Campisano |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Bone marrow Dendritic cell Melanoma Vaccine apoptotic and necrotic cell vaccine B7 antigen CD11b antigen CD83 antigen CD86 antigen dendritic cell vaccine glycoprotein p 15095 granulocyte macrophage colony stimulating factor interleukin 12 major histocompatibility antigen class 2 unclassified drug vaccine animal cell animal experiment animal model article bone marrow cell differentiation cell fractionation cell population cell type coculture controlled study dendritic cell immunogenicity macrophage male mouse neutrophil nonhuman phagocyte phenotype precursor priority journal tumor cell Animals Antigen Presentation Antigens, CD11c Antigens, Surface Bone Marrow Cells Cancer Vaccines Cell Differentiation Cell Line, Tumor Coculture Techniques Dendritic Cells Granulocyte-Macrophage Colony-Stimulating Factor Interleukin-12 Lymphocyte Activation Male Melanoma, Experimental Mice Mice, Inbred BALB C Mice, Inbred C57BL Neutrophils |
| spellingShingle |
Bone marrow Dendritic cell Melanoma Vaccine apoptotic and necrotic cell vaccine B7 antigen CD11b antigen CD83 antigen CD86 antigen dendritic cell vaccine glycoprotein p 15095 granulocyte macrophage colony stimulating factor interleukin 12 major histocompatibility antigen class 2 unclassified drug vaccine animal cell animal experiment animal model article bone marrow cell differentiation cell fractionation cell population cell type coculture controlled study dendritic cell immunogenicity macrophage male mouse neutrophil nonhuman phagocyte phenotype precursor priority journal tumor cell Animals Antigen Presentation Antigens, CD11c Antigens, Surface Bone Marrow Cells Cancer Vaccines Cell Differentiation Cell Line, Tumor Coculture Techniques Dendritic Cells Granulocyte-Macrophage Colony-Stimulating Factor Interleukin-12 Lymphocyte Activation Male Melanoma, Experimental Mice Mice, Inbred BALB C Mice, Inbred C57BL Neutrophils Campisano, S. Mac Keon, S. Gazzaniga, S. Ruiz, M.S. Traian, M.D. Mordoh, J. Wainstok, R. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| topic_facet |
Bone marrow Dendritic cell Melanoma Vaccine apoptotic and necrotic cell vaccine B7 antigen CD11b antigen CD83 antigen CD86 antigen dendritic cell vaccine glycoprotein p 15095 granulocyte macrophage colony stimulating factor interleukin 12 major histocompatibility antigen class 2 unclassified drug vaccine animal cell animal experiment animal model article bone marrow cell differentiation cell fractionation cell population cell type coculture controlled study dendritic cell immunogenicity macrophage male mouse neutrophil nonhuman phagocyte phenotype precursor priority journal tumor cell Animals Antigen Presentation Antigens, CD11c Antigens, Surface Bone Marrow Cells Cancer Vaccines Cell Differentiation Cell Line, Tumor Coculture Techniques Dendritic Cells Granulocyte-Macrophage Colony-Stimulating Factor Interleukin-12 Lymphocyte Activation Male Melanoma, Experimental Mice Mice, Inbred BALB C Mice, Inbred C57BL Neutrophils |
| description |
We have initially shown that DC/ApoNec vaccine can induce protection against the poorly immunogenic B16F1 melanoma in mice. The population of DC obtained for vaccination after 7. days culture with murine GM-CSF is heterogeneous and presents about 60% of CD11c+ DC. Therefore, our purpose was to identify the phenotype of the cells obtained after differentiation and its immunogenicity once injected. DC were separated with anti-CD11c microbeads and the two populations identified in terms of CD11c positivity (DC+ and DC-) were also studied. Approximately 26.6% of the cells in DC+ fraction co-expressed CD11c+ and F4/80 markers and 75.4% were double positive for CD11c and CD11b markers. DC+ fraction also expressed Ly6G. DC- fraction was richer in CD11c-/F4/80+ macrophages (44.7%), some of which co-expressed Ly6G (41.8%), and F4/80-/Ly6-G+ neutrophils (34.6%). Both DC+ and DC- fractions displayed similar capacity to phagocyte and endocyte antigens and even expressed levels of MHC Class II and CD80, CD83 and CD86 costimulatory molecules similar to those in the DC fraction. However, only DC/ApoNec vaccine was capable to induce protection in mice (p<. 0.01). After 24. h co-culture, no detectable level of IL-12 was recorded in DC/ApoNec vaccine, either in supernatant or intracellularly. Therefore, the protection obtained with DC/ApoNec vaccine seemed to be independent of the vaccine's ability to secrete this inflammatory cytokine at the time of injection. In conclusion, we demonstrated that all cell types derived from the culture of mouse bone marrow with GM-CSF are necessary to induce antitumor protection in vivo. © 2012 Elsevier Ltd. |
| format |
JOUR |
| author |
Campisano, S. Mac Keon, S. Gazzaniga, S. Ruiz, M.S. Traian, M.D. Mordoh, J. Wainstok, R. |
| author_facet |
Campisano, S. Mac Keon, S. Gazzaniga, S. Ruiz, M.S. Traian, M.D. Mordoh, J. Wainstok, R. |
| author_sort |
Campisano, S. |
| title |
Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| title_short |
Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| title_full |
Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| title_fullStr |
Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| title_full_unstemmed |
Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors |
| title_sort |
anti-melanoma vaccinal capacity of cd11c-positive and -negative cell populations present in gm-csf cultures derived from murine bone marrow precursors |
| url |
http://hdl.handle.net/20.500.12110/paper_0264410X_v31_n2_p354_Campisano |
| work_keys_str_mv |
AT campisanos antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT mackeons antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT gazzanigas antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT ruizms antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT traianmd antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT mordohj antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors AT wainstokr antimelanomavaccinalcapacityofcd11cpositiveandnegativecellpopulationspresentingmcsfculturesderivedfrommurinebonemarrowprecursors |
| _version_ |
1807324477139189760 |